Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]



BLUE BELL, PAMarch 24, 2004 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced the appointment of Del Humphreys to the newly created position of Senior Vice President of Sales.  Mr. Humphreys will be responsible for all areas related to the Company’s sales operations and will report directly to Robert F. Apple, InKine’s Chief Operating and Financial Officer.

 “We are delighted to have someone with Del’s pharmaceutical experience and sales expertise join our senior management team,” said Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine.  “Del’s depth of knowledge in the pharmaceutical sales arena will greatly benefit our Company and assist us in maximizing the potential of our product portfolio,” added Dr. Jacob. 

 Mr. Humphreys joins InKine from Wyeth and brings with him approximately 30-years of pharmaceutical experience in areas including: sales force management, product management, trade, managed care, sales training and institutional sales.

 “Del has assumed a key position within InKine and we are excited about working with him,” said Mr. Apple.  “His proven track record for delivering results makes him a strong addition to our team.  We are thrilled to have his experience and skill leading our sales organization,” added Mr. Apple.

 “I am very happy to join InKine Pharmaceutical and work with its management team,” said Mr. Humphreys.  “InKine’s VisicolÒ franchise is poised for growth through indication extensions, product enhancements and sales force expansion.  I am looking forward to participating in the future growth of our current products and potential future opportunities” added Mr. Humphreys.

 About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol® is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat®, is an oral hyoscyamine spray for the treatment of a variety of indications.  Additionally, the Company has filed a provisional patent application for the development of a new generation purgative, for which clinical trials are expected to initiate during 2004, and is developing Colirest™, which is in clinical trials for the treatment of Crohn's disease. For further information, please visit InKine on its web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.